Vizimpro (dacomitinib)

To our knowledge, ARIA is the largest real-world study of dacomitinib's efficacy and safety. Final analysis of this study showed substantial clinical efficacy of dacomitinib and revealed treatment patterns, such as starting dose, in the real world. Safety data were consistent with dacomitinib's known safety profile. These results support first-line dacomitinib use in Asian patients with EGFR mutation-positive advanced NSCLC.

P=N/A, N=180, Recruiting, Pfizer | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026

This NMA revealed that cases with EGFR-mutated NSCLC may benefit from different first-line treatment regimens according to their clinicopathological characteristics. On the whole, osimertinib plus CT and amivantamab plus lazertinib emerged as the most noticeable treatment modalities for such cases. (PROSPERO ID: CRD42024506995).

The patient was treated sequentially with three generations of EGFR TKIs-gefitinib, osimertinib, and dacomitinib-while continuing immunosuppressive therapy for graft function. To our knowledge, this is the first reported case of an EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient benefiting from sequential multi-TKI therapy. This case underscores the importance of vigilant cancer surveillance in transplant recipients and suggests that individualized TKI sequencing may offer clinical benefit, although further evidence is required.

P=N/A, N=180, Recruiting, Pfizer | Trial completion date: Mar 2026 --> Oct 2025 | Trial primary completion date: Mar 2026 --> Oct 2025

And dacomitinib, regorafenib, fruquintinib, vandetanib, and panitumumab were the top 5 drugs with high risk. Non-antitumor drugs were all moderate risk, involving atorvastatin, zoledronic acid, amiodarone hydrochloride, lithium, and teduglutide...The number of related adverse event reports increased year by year. The results of this study provided the relevant basis for pharmacovigilance, and provided the basis for strengthening drug safety and making correct drug decision in clinical practice.

P2, N=30, Active, not recruiting, Shanghai Chest Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2027

The drug sensitivity analysis showed that dacomitinib and talazoparib may serve as anti-ESCC drugs through targeting MAPK14. The in vitro experiments showed that knockdown of NEURL3 inhibited the proliferation and motility of ESCC cells. Based on the URGs and DRGs prognostic signature, a novel nomogram was constructed that could serve as a potentially reliable prognostic model and provide theoretical basis for uncovering potential therapeutic target in the treatment of ESCC.

ScRNA-seq delineated three PCa cell clusters, with high-risk subtypes being sensitive to bendamustine/dacomitinib and resistant to apalutamide/neratinib. This study establishes a TME-driven prognostic framework that connects immune heterogeneity, genomic instability, and therapeutic resistance in PCa. By pinpointing metabolic dependencies and subtype-specific vulnerabilities, our findings provide actionable strategies to circumvent treatment failure, such as targeting energy metabolism or tailoring therapies based on resistance signatures.

Dacomitinib demonstrated robust systemic and intracranial efficacy in patients with NSCLC harboring EGFR mutations and severe brain metastases, with acceptable adverse events, thereby supporting its use as a first-line treatment.

P=N/A, N=180, Recruiting, Pfizer | Enrolling by invitation --> Recruiting

P1/2, N=35, Completed, The Netherlands Cancer Institute | Unknown status --> Completed